Confronto
Gonadorelin vs. Teduglutid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
33515-09-2
197922-42-2
Peso molecolare
1182.29 g/mol
3752.13 g/mol
Emivita
0.1 h
nessun dato
Sequenza
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2nessun dato
Meccanismo d'azione
Gonadorelin
Gonadorelin acts as an agonist at the GnRH receptor on the gonadotroph cells of the pituitary and triggers release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The temporal pattern of receptor exposure is decisive: pulsatile administration mimics the natural hypothalamic secretory rhythm and sustains LH/FSH release, whereas continuous exposure leads to receptor internalisation and desensitisation with subsequent paradoxical suppression of gonadotropins. The latter principle is exploited therapeutically by longer-acting GnRH agonists.
Teduglutid
Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.
Base di evidenze
Evidenza più alta
Studio sull'uomo
RCT sull'uomo
Studi
4
2
di cui sull'uomo
4
2
Effetti registrati
4
2
Contraddizioni aperte
1
0
Eventi avversi documentati
2
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Gonadorelin and Teduglutid?
- Gonadorelin is classified as "Ricerca (altro)", while Teduglutid is classified as "Ricerca (altro)". Gonadorelin: Gonadorelin is the synthetic decapeptide with an amino-acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH). Historically approved in several countries for diagnostic testing of pituitary function and for fertility indications (pump systems). A defining feature is the opposite effect of pulsatile versus continuous administration: pulsatile stimulates, continuous leads to receptor desensitisation. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Gonadorelin or Teduglutid?
- The highest available evidence level is "Studio sull'uomo" for Gonadorelin and "RCT sull'uomo" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Gonadorelin and Teduglutid in Germany and the United States?
- Germania: Gonadorelin — Su prescrizione, Teduglutid — Su prescrizione. Stati Uniti: Gonadorelin — Su prescrizione, Teduglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.